Loading clinical trials...
Loading clinical trials...
Evaluation of Potential Benefits of Trimetazidine in the Management of Patients With Metabolic Associated Steatotic Liver Disease (MASLD)
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD
the study will evaluate the possible benefits of trimetazidine when added to pateints with metabolic associated fatty liver disease
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Beni-Suef university
Banī Suwayf, Beni Suweif Governorate, Egypt
Start Date
December 10, 2023
Primary Completion Date
June 1, 2024
Completion Date
November 30, 2024
Last Updated
July 11, 2025
60
ACTUAL participants
Trimetazidine
DRUG
Conventional therapy
DRUG
Placebo
DRUG
Lead Sponsor
October 6 University
NCT07122700
NCT06764056
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions